NEW YORK ─ Life sciences firm Bayer and genomic analysis company ArcherDx on Thursday announced a global collaboration for the development and commercialization of a next-generation sequencing-based companion diagnostic test for Bayer's Vitrakvi (larotrectinib), which targets cancers with fusions in neurotrophic receptor tyrosine kinase (NTRK) genes.